RECRUITINGOBSERVATIONAL
Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
Identification Of Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer. Tox-DXd: a Prospective, Observational Study
About This Trial
the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a non-negligible rate of adverse events that may lead to treatment discontinuation and/or the onset of pneumonitis/interstitial lung disease (ILD) The aim of the study is to identify and describe potentially predictive markers related to the onset of relevant T-DXd-related toxicities
Who May Be Eligible (Plain English)
Who May Qualify:
- Male or female, aged at least 18 years.
- Histologically documented invasive breast cancer, either HER2-positive or HER2-low/ultralow.
- Candidate to receive T-DXd as per standard practice.
- Consent for the provision of blood samples for exploratory analyses.
Who Should NOT Join This Trial:
- Operable, non-metastatic breast cancer
- Unwillingness to provide additional blood draws
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Male or female, aged at least 18 years.
* Histologically documented invasive breast cancer, either HER2-positive or HER2-low/ultralow.
* Candidate to receive T-DXd as per standard practice.
* Consent for the provision of blood samples for exploratory analyses.
Exclusion Criteria:
* Operable, non-metastatic breast cancer
* Unwillingness to provide additional blood draws
Treatments Being Tested
OTHER
T-DXd toxicity marker identification
to find potential predictive markers associated with T-DXd-related toxicities
Locations (1)
European Institute of Oncolgy
Milan, Italy